title: The carbon monoxide releasing molecule CORM-2 attenuates Pseudomonas aeruginosa biofilm formation.
abstract: Chronic infections resulting from biofilm formation are difficult to eradicate with current antimicrobial agents and consequently new therapies are needed. This work demonstrates that the carbon monoxide-releasing molecule CORM-2, previously shown to kill planktonic bacteria, also attenuates surface-associated growth of the gram-negative pathogen Pseudomonas aeruginosa by both preventing biofilm maturation and killing bacteria within the established biofilm. CORM-2 treatment has an additive effect when combined with tobramycin, a drug commonly used to treat P. aeruginosa lung infections. CORM-2 inhibited biofilm formation and planktonic growth of the majority of clinical P. aeruginosa isolates tested, for both mucoid and non-mucoid strains. While CORM-2 treatment increased the production of reactive oxygen species by P. aeruginosa biofilms, this increase did not correlate with bacterial death. These data demonstrate that CO-RMs possess potential novel therapeutic properties against a subset of P. aeruginosa biofilm related infections.
authors.affiliation: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States of America.
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Murray
authors.forename: Chinweike
authors.initials: C
authors.lastname: Okegbe
authors.forename: Yuan
authors.initials: Y
authors.lastname: Gao
authors.forename: Barbara I
authors.initials: BI
authors.lastname: Kazmierczak
authors.forename: Roberto
authors.initials: R
authors.lastname: Motterlini
authors.forename: Lars E P
authors.initials: LE
authors.lastname: Dietrich
authors.forename: Emanuela M
authors.initials: EM
authors.lastname: Bruscia
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D018441:Biofilms / Q000187:drug effects*; D002248:Carbon Monoxide / Q000378:metabolism*; D004847:Epithelial Cells / Q000382:microbiology; D006801:Humans; D009942:Organometallic Compounds / Q000494:pharmacology*; D011552:Pseudomonas Infections / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D014031:Tobramycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D017382:Reactive Oxygen Species; C447082:tricarbonyldichlororuthenium (II) dimer; D002248:Carbon Monoxide; D014031:Tobramycin